About

Steven Goodman, MD, MHS, PhD, is a Professor of Epidemiology and Population Health, of Medicine (Primary Care and Population Health), and by courtesy, of Health Policy at Stanford University. He serves as Associate Dean of Clinical and Translational Research and is the founder and director of the Stanford Program on Research Rigor and Reproducibility (SPORR), which aims to teach and implement best practices in reproducible research within the School of Medicine. Goodman is also co-founder and co-director of the Meta-research Innovation Center at Stanford (METRICS), dedicated to examining and improving the reproducibility and efficiency of biomedical research. His research focuses on the measurement, conceptualization, and synthesis of research evidence, with particular emphasis on Bayesian approaches to quantitation and qualitative methods from the philosophy of science. He is interested in developing methods to use shared data to confirm and extend published science, as well as exploring the connections between ethics, clinical research, and policy making. Additionally, Goodman is committed to developing curricula and new models for teaching scientific practices, covering question development, study design, conduct, analysis, and inference. He teaches courses on clinical research methods, scientific and statistical reasoning, and evaluation of diagnostic and predictive technologies. Throughout his career, Goodman has held numerous leadership roles, served on various national committees, and received multiple awards, including election to the National Academy of Medicine in 2020.

Research topics

• Pathology
• Medicine
• Surgery
• Internal medicine
• Immunology
• Cell biology
• Anatomy
• Biology
• Intensive care medicine
• Cancer research
• Physical therapy

Selected publications

• Modulation of the Inflammatory Response and Bone Healing

  Frontiers in Endocrinology · 2020 · 492 citations

  Senior authorCorresponding
  • Medicine
  • Immunology
  • Cancer research

  The optimal treatment for complex fractures and large bone defects is an important unsolved issue in orthopedics and related specialties. Approximately 5-10% of fractures fail to heal and develop non-unions. Bone healing can be characterized by three partially overlapping phases: the inflammatory phase, the repair phase, and the remodeling phase. Eventual healing is highly dependent on the initial inflammatory phase, which is affected by both the local and systemic responses to the injurious stimulus. Furthermore, immune cells and mesenchymal stromal cells (MSCs) participate in critical inter-cellular communication or crosstalk to modulate bone healing. Deficiencies in this inter-cellular exchange, inhibition of the natural processes of acute inflammation, and its resolution, or chronic inflammation due to a persistent adverse stimulus can lead to impaired fracture healing. Thus, an initial and optimal transient stage of acute inflammation is one of the key factors for successful, robust bone healing. Recent studies demonstrated the therapeutic potential of immunomodulation for bone healing by the preconditioning of MSCs to empower their immunosuppressive properties. Preconditioned MSCs (also known as "primed/ licensed/ activated" MSCs) are cultured first with pro-inflammatory cytokines (e.g., TNFα and IL17A) or exposed to hypoxic conditions to mimic the inflammatory environment prior to their intended application. Another approach of immunomodulation for bone healing is the resolution of inflammation with anti-inflammatory cytokines such as IL4, IL10, and IL13. In this review, we summarize the principles of inflammation and bone healing and provide an update on cellular interactions and immunomodulation for optimal bone healing.

  DOI

• Guidelines for clinical diagnosis and treatment of osteonecrosis of the femoral head in adults (2019 version)

  Journal of Orthopaedic Translation · 2020 · 436 citations

  • Medicine
  • Intensive care medicine
  • Physical therapy

  Osteonecrosis of the femoral head (ONFH) is a common and refractory disease in orthopaedic clinics. The number of patients with ONFH is increasing worldwide every year. There are an estimated 8.12 million patients with nontraumatic osteonecrosis in China alone. Treatment of nontraumatic osteonecrosis has always been a clinical challenge for orthopaedic surgeons. To further standardize diagnosis and treatment of ONFH, these guidelines provide not only basic diagnosis, treatment, and evaluation systems for ONFH but also expert advice and standards in many aspects, including epidemiology, aetiology, diagnostic criteria, pathological staging, prevention and treatment options, and postoperative rehabilitation. The aetiological factors of ONFH can currently be divided into two major categories: traumatic and nontraumatic; however, the specific pathological mechanism of ONFH is not completely clear. Currently, the staging system of ONFH formulated by the Association Research Circulation Osseous is widely used in clinical practice. Based on the changes in the intraosseous blood supply at different stages, the corresponding nonsurgical and surgical treatments are recommended, and when there are risk factors for possible ONFH, certain preventive measures to avoid the occurrence of osteonecrosis are recommended. These guidelines provide brief classification criteria and treatment regimen for osteonecrosis. Specification of the aetiology, treatment plan based on comprehensive consideration of the different stages of osteonecrosis, hip function, age, and occupation of the patients are important steps in diagnosis and developing treatment strategies. TRANSLATIONAL POTENTIAL OF THIS ARTICLE: New advances in the epidemiology, etiology, pathophysiology, imaging, diagnosis and treatment of ONFH have been renewed in this revision. This guideline can be used for reference by orthopedic professionals and researchers, and for standardized diagnosis and treatment management under the clinical guidance, which is conducive to the prevention, treatment and further research of ONFH, improving the diagnosis and treatment level, making patients' symptoms under good control, and improving their quality of life.

  DOI

• Articular cartilage regeneration by activated skeletal stem cells

  Nature Medicine · 2020 · 352 citations

  • Cell biology
  • Medicine
  • Biology
  DOI

Recent grants

• NIH Grant R01AR055650

  NIH · $3.3M · 2017

• Enhanced Bone Healing Around Implants by Transplanted NF-kB Driven Immunomodulating MSCs

  NIH · $346k · 2012–2022

• NIH Grant U01MH046725

  NIH · $2.5M · 1995

• NIH Grant R21AR053189

  NIH · $373k · 2008

• Customized MSCs to Enhance Healing of Bone Defects

  NIH · $1.4M · 2018–2022

Frequent coauthors

• William J. Maloney

  Stanford Medicine

  187 shared

• James I. Huddleston

  Stanford University

  157 shared

• Jukka Pajarinen

  Helsinki University Hospital

  130 shared

• Zhenyu Yao

  Shandong Center for Disease Control and Prevention

  121 shared

• David J. Schurman

  Stanford Medicine

  120 shared

• Robert L. Smith

  Baylor Medical Center at Garland

  114 shared

• Derek F. Amanatullah

  114 shared

• Ting Ma

  Shenzhen Institute of Information Technology

  99 shared

Labs

• Stanford Program on Research Rigor and Reproducibility (SPORR)PI

Education

• B.A., Biochemistry and Applied Math

  Harvard

• M.D.

  NYU

• M.S., Biostatistics

  Johns Hopkins

• Ph.D., Epidemiology

  Johns Hopkins

Awards & honors

• Spinoza Chair in Medicine, University of Amsterdam (2016)
• Abraham Lilienfeld Award, American College of Epidemiology (…
• Lifetime Fellow, American College of Epidemiology (2019)
• Elected Member, National Academy of Medicine (2020)
• Elected Fellow, Johns Hopkins Society of Scholars (2022)

Similar researchers at Stanford University

• Yi Cuih-287
• Zhenan Baoh-224
• Karl Deisserothh-218
• Michael Snyderh-215
• Roger Blandfordh-205